Observational studyActa neurologica Belgica2026
Impact of ocrelizumab on quality of life, fatigue, and depression among multiple sclerosis patients.
Observational study in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOcrelizumab, a CD20-targeting monoclonal antibody, is a novel disease-modifying therapy for relapsing-remitting multiple sclerosis (MS) and primary progressive multiple sclerosis. Despite established efficacy in reducing relapse rates and disease progression, its impact on patient-reported outcomes (PROs) such as health-related quality of life (HRQOL), depression, and fatigue remains understudied.
methodsThis single-arm observational study included 30 MS patients receiving ocrelizumab at a tertiary center in Tehran, Iran. Selected PROs were assessed at 0-, 6-, and 12-month time points using the Medical Outcomes Study Short Form-36 for HRQOL, the Beck Depression Inventory-II for depression severity, and the Fatigue Severity Scale for fatigue. Longitudinal changes were analyzed using linear mixed models. Linear regression models were used to explore associations between patient demographics, clinical characteristics, and PRO scores at baseline.
resultsAt baseline, participants had impaired HRQOL across multiple domains. Over 12 months, significant improvements were observed in general health (P < .001), vitality (P = .032), and role-emotional (P = .012), along with increases in the mental (P = .026) and physical (P = .020) component summary scores. Depression severity decreased significantly (P = .029), but no significant changes were detected in fatigue levels (P = .818). Higher baseline EDSS was associated with lower physical functioning (P < .001) and general health (P = .023).
conclusionOcrelizumab treatment was associated with improved physical and mental HRQOL and reduced depression severity in MS patients.
Indexed as
Identifiers
41370024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.